NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 2020
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Loss of Exclusivity
LOE Date
Sep 3, 2041
188 months away
Patent Expiry
Sep 3, 2041
Exclusivity Expiry
Sep 3, 2027
Company
Curium Pharma
France - Paris